Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220989697> ?p ?o ?g. }
- W4220989697 endingPage "982" @default.
- W4220989697 startingPage "959" @default.
- W4220989697 abstract "Biological therapies have revolutionized the treatment of disease across a number of therapeutic areas including retinal diseases. However, on occasion, such treatments may be relatively more expensive compared to small molecule therapies. This can restrict patient access and treatment length leading to suboptimal clinical outcomes. Several biosimilar candidates of ranibizumab and aflibercept are currently in development and the first biosimilar of ranibizumab received EMA approval in August and FDA approval in September 2021. Biosimilars are biological medicines that are highly similar to an already-approved biological medicine (reference product). The physicochemical and clinical similarity of a biosimilar is determined by a rigorous analytical and clinical program, including extensive pharmacokinetic and pharmacodynamic analysis with phase III equivalence studies where appropriate. These phase III studies are carried out in a patient population that is representative of all of the potential approved therapeutic indications of the originator product and the most sensitive for detecting potential differences between the biosimilar and the reference product. Biosimilars have been used successfully across a wide range of therapeutic areas for the past 15 years where they have achieved substantial cost savings that can be reinvested into healthcare systems without affecting the quality of patient care. The current review provides an introduction to biosimilars with the aim of preparing retinal specialists for discussing these products with their patients." @default.
- W4220989697 created "2022-04-03" @default.
- W4220989697 creator A5003610646 @default.
- W4220989697 creator A5030673049 @default.
- W4220989697 creator A5064958412 @default.
- W4220989697 creator A5068072154 @default.
- W4220989697 creator A5071809610 @default.
- W4220989697 creator A5083564913 @default.
- W4220989697 date "2022-03-12" @default.
- W4220989697 modified "2023-10-16" @default.
- W4220989697 title "An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review" @default.
- W4220989697 cites W1147832057 @default.
- W4220989697 cites W1251997985 @default.
- W4220989697 cites W1481978003 @default.
- W4220989697 cites W1551539224 @default.
- W4220989697 cites W1588519937 @default.
- W4220989697 cites W1752472043 @default.
- W4220989697 cites W1786299986 @default.
- W4220989697 cites W1965755128 @default.
- W4220989697 cites W1974160275 @default.
- W4220989697 cites W1977926335 @default.
- W4220989697 cites W1979325667 @default.
- W4220989697 cites W1980282196 @default.
- W4220989697 cites W2020713670 @default.
- W4220989697 cites W2023193839 @default.
- W4220989697 cites W2030711540 @default.
- W4220989697 cites W2034350610 @default.
- W4220989697 cites W2050887885 @default.
- W4220989697 cites W2062838995 @default.
- W4220989697 cites W2074734789 @default.
- W4220989697 cites W2082425581 @default.
- W4220989697 cites W2091995353 @default.
- W4220989697 cites W2110270840 @default.
- W4220989697 cites W2140200788 @default.
- W4220989697 cites W2167418359 @default.
- W4220989697 cites W2203977709 @default.
- W4220989697 cites W2223317003 @default.
- W4220989697 cites W2233101323 @default.
- W4220989697 cites W2277879584 @default.
- W4220989697 cites W2290587826 @default.
- W4220989697 cites W2330425005 @default.
- W4220989697 cites W2336901813 @default.
- W4220989697 cites W2494623578 @default.
- W4220989697 cites W2506318659 @default.
- W4220989697 cites W2522843224 @default.
- W4220989697 cites W2543281533 @default.
- W4220989697 cites W2552690718 @default.
- W4220989697 cites W2581281042 @default.
- W4220989697 cites W2581549770 @default.
- W4220989697 cites W2588687669 @default.
- W4220989697 cites W2606245581 @default.
- W4220989697 cites W2610804525 @default.
- W4220989697 cites W2613299853 @default.
- W4220989697 cites W2661134095 @default.
- W4220989697 cites W2736727076 @default.
- W4220989697 cites W2741340135 @default.
- W4220989697 cites W2743639829 @default.
- W4220989697 cites W2745410586 @default.
- W4220989697 cites W2750699013 @default.
- W4220989697 cites W2753749775 @default.
- W4220989697 cites W2759307758 @default.
- W4220989697 cites W2759349664 @default.
- W4220989697 cites W2762604306 @default.
- W4220989697 cites W2763705296 @default.
- W4220989697 cites W2784031367 @default.
- W4220989697 cites W2791224008 @default.
- W4220989697 cites W2791685499 @default.
- W4220989697 cites W2791960968 @default.
- W4220989697 cites W2793818576 @default.
- W4220989697 cites W2793866077 @default.
- W4220989697 cites W2796428896 @default.
- W4220989697 cites W2804391440 @default.
- W4220989697 cites W2804886519 @default.
- W4220989697 cites W2831879655 @default.
- W4220989697 cites W2885145206 @default.
- W4220989697 cites W2885678144 @default.
- W4220989697 cites W2886098280 @default.
- W4220989697 cites W2886321911 @default.
- W4220989697 cites W2890461594 @default.
- W4220989697 cites W2894046119 @default.
- W4220989697 cites W2894239243 @default.
- W4220989697 cites W2894698382 @default.
- W4220989697 cites W2900342679 @default.
- W4220989697 cites W2900361267 @default.
- W4220989697 cites W2904249805 @default.
- W4220989697 cites W2910805830 @default.
- W4220989697 cites W2913809318 @default.
- W4220989697 cites W2920298278 @default.
- W4220989697 cites W2921181370 @default.
- W4220989697 cites W2930414230 @default.
- W4220989697 cites W2933622020 @default.
- W4220989697 cites W2939462658 @default.
- W4220989697 cites W2946777014 @default.
- W4220989697 cites W2949358313 @default.
- W4220989697 cites W2952089805 @default.
- W4220989697 cites W2952465403 @default.
- W4220989697 cites W2953498715 @default.
- W4220989697 cites W2963334060 @default.